Lifordi Immunotherapeutics Announces Major Strategic Investment Led by Sanofi Ventures, Strengthening Support from Existing Investors and Advancing a Transformative ADC Platform for Autoimmune and Inflammatory Diseases Lifordi Immunotherapeutics, Inc., a…
ChristianaCare Establishes Organoid Core to Power Precision Cancer Treatment ChristianaCare’s Cawley Center for Translational Cancer Research has launched a groundbreaking organoid core—marking the first time such an advanced, patient-specific modeling…
Henlius and Organon Announce U.S. FDA Approval of POHERDY®, the First Interchangeable Pertuzumab Biosimilar in the United States Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a major…
Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer, Strengthening Clinical Leadership Amid Advancement of Novel Immunomodulatory Programs Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company focused…
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Strategy for BOT/BAL and Early-Access Programs Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its long-standing…
Enanta Pharmaceuticals Reports Fiscal Fourth Quarter and Full-Year 2025 Financial Results and Highlights Major Clinical Advancements Across Virology and Immunology Programs Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a…
Sonoma Biotherapeutics Announces Leadership Transition as Stephen Dilly, MBBS, PhD, Becomes President and CEO; Co-founder Jeff Bluestone, PhD, Assumes Advisory Role Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company advancing engineered…
Solve Therapeutics Raises $120 Million to Accelerate Next-Generation ADC Development for Solid Tumors Solve Therapeutics, a rapidly advancing clinical-stage biotechnology company focused on creating best-in-class antibody–drug conjugates (ADCs) for the…
Scribe Therapeutics Highlights Major ASCVD Lipid Insights at AHA 2025 Scribe Therapeutics Inc. (“Scribe”), a leading genetic medicines company engineering next-generation in vivo CRISPR-based treatments, unveiled a series of breakthrough…
Johnson & Johnson Strengthens Oncology Leadership With $3.05 Billion Acquisition of Halda Therapeutics and Its Next-Generation RIPTAC™ Platform Johnson & Johnson (NYSE: JNJ) announced that it has entered into a…
JSR Life Sciences Announces Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings, Marking a Significant Strategic Realignment in Oncology Research Services JSR Life Sciences LLC (“JSR Life Sciences”), a…
